News

For Pharmetheus, our corporate social responsibility (CSR) ambitions are to become an even more sustainable and responsible company. Like all initiatives within Pharmetheus, our CSR strategy stems from our vision and core

Our engagement in PBPK-QSP takes many forms! We’ve recently kicked off three new research projects, about i) an infrastructure for streamlining processes of PBPK projects, ii) a framework for evaluating the performance

Do you have experience working as Project Coordinator? Do you want to be part of a fantastic team in an expanding international organization? Pharmetheus keeps moving forward and is looking to grow

Pharmetheus is a proud sponsor, workshop organizer, poster author, and attendee delegation to WCoP in March. Hats off to the hosts for fantastic organization as illustrated in this video.

Pharmetheus’ webinar regarding A Growing Network of Open Science: PBPK modelling of Drug–Drug Interactions with the Open Systems Pharmacology Suite, was well attended and received two weeks ago. If you missed it,

Imeglimin (TWYMEEG®), an orally administered first-in-class treatment for type 2 diabetes, recently received its first approval in Japan. Population PK and PKPD models have played an important role in supporting drug development

We are very happy to welcome Patrik Ejerhed as a Financial Controller. Patrik’s experience includes financial auditing at PricewaterhouseCoopers and KPMG. He will be based in Uppsala. See Patrik’s bio here.

Interested in PBPK? Join this one-day workshop held on 28th March 2022, in connection with WCoP, led by Pharmetheus’ PBPK experts. Read more here.

All at Pharmetheus wish you God Jul & Gott Nytt År! We are pleased and privileged to have collaborated with many and varied clients throughout 2021 and to have advanced our collective